Development of symptomatic brain metastases after chemoradiotherapy for stage III non-small cell lung cancer: Does the type of chemotherapy regimen matter?

Lizza E.L. Hendriks; Anita J.W.M. Brouns; Mohammad Amini; Wilma Uyterlinde; Robin Wijsman; Jan Bussink; Bonne Biesma; S. Bing Oei; Jos A. Stigt; Gerben P. Bootsma; José S.A. Belderbos; Dirk K.M. De Ruysscher; Michel M. Van den Heuvel; Anne Marie C. Dingemans

doi:10.1016/j.lungcan.2016.09.008

Development of symptomatic brain metastases after chemoradiotherapy for stage III non-small cell lung cancer: Does the type of chemotherapy regimen matter?

Lizza E.L. Hendriks^*
, Anita J.W.M. Brouns
, Mohammad Amini
, Wilma Uyterlinde
, Robin Wijsman
, Jan Bussink
, Bonne Biesma
, S. Bing Oei
, Jos A. Stigt
, Gerben P. Bootsma
, José S.A. Belderbos
, Dirk K.M. De Ruysscher
, Michel M. Van den Heuvel
, Anne Marie C. Dingemans

^*Corresponding author for this work

Maastricht University
Zuyderland Medical Center (Heerlen)
Jeroen Bosch Ziekenhuis
The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital
Radboud University Medical Center
Dr. Bernard Verbeeten Instituut
Isala Clinics

Research output: Contribution to journal › Article › Academic › peer-review

13 Citations (Scopus)

27 Downloads (Pure)

Abstract

Objectives:

Symptomatic brain metastases (BM) occur frequently after chemoradiotherapy (CRT) for stage III NSCLC. Aim of the current study was to determine whether the specific chemotherapy used in a CRT regimen influences BM development.

Materials and methods:

Retrospective multicenter study including all consecutive stage III NSCLC who completed CRT. Primary endpoints: symptomatic BM development, whether this was the only site of first relapse. Differences between regimens were assessed with a logistic regression model including known BM risk factors and the specific chemotherapy: concurrent versus sequential (cCRT/sCRT), within cCRT: daily low dose cisplatin (LDC)-cyclic dose polychemotherapy; LDC-(non-)taxane cyclic dose; LDC–polychemotherapy subgroups of ≥50 patients.

Results:

Between January 2006 and June 2014, 838 patients were eligible (737 cCRT, 101 sCRT). 18.2% developed symptomatic BM, 8.0% had BM as only site of first relapse. BM patients were significantly younger, female, had more advanced N-stage and had adenocarcinoma histology. In both cCRT and sCRT BM were found in 18% (p = 0.904). In cyclic dose cCRT (N = 346) and LDC (N = 391) BM were found in 18.8% and 17.9%, respectively (p = 0.757). In 7.2% and 8.7%, respectively, BM were the only site of first relapse (p = 0.463). The chemotherapy used (cCRT versus sCRT) had no influence on BM development, not for all brain relapses nor as only site of first relapse (OR 0.88 (p = 0.669), OR 0.93 (p = 0.855), respectively). LDC versus cyclic dose cCRT was not significantly different: neither for all brain relapses nor as only site of first relapse (OR 0.96 (p = 0.819), OR 1.21 (p = 0.498), respectively). Comparable results were found for LDC versus cyclic dose non-taxane (N = 277) and cyclic dose taxane regimens (N = 69) and for cCRT regimens with ≥50 patients (LDC versus cisplatin/etoposide (N = 188), cisplatin/vinorelbin (N = 65), weekly cisplatin/docetaxel (N = 60)).

Conclusion:

approximately 18% developed symptomatic BM after stage III diagnosis, not dependent on type of chemotherapy regimen used within a CRT treatment.

Original language	English
Pages (from-to)	68-75
Number of pages	8
Journal	Lung Cancer
Volume	101
DOIs	https://doi.org/10.1016/j.lungcan.2016.09.008
Publication status	Published - Nov 2016
Externally published	Yes

Bibliographical note

Publisher Copyright:
© 2016 Elsevier Ireland Ltd

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/j.lungcan.2016.09.008Licence: CC BY

Development of symptomatic brain metastases after chemoradiotherapy for stage III non-small cell lung cancerFinal published version, 338 KBLicence: CC BY

Cite this

Hendriks, L. E. L., Brouns, A. J. W. M., Amini, M., Uyterlinde, W., Wijsman, R., Bussink, J., Biesma, B., Oei, S. B., Stigt, J. A., Bootsma, G. P., Belderbos, J. S. A., De Ruysscher, D. K. M., Van den Heuvel, M. M., & Dingemans, A. M. C. (2016). Development of symptomatic brain metastases after chemoradiotherapy for stage III non-small cell lung cancer: Does the type of chemotherapy regimen matter? Lung Cancer, 101, 68-75. https://doi.org/10.1016/j.lungcan.2016.09.008

@article{ae0ebcd5e0b54d2eb835d985ff3b5e70,

title = "Development of symptomatic brain metastases after chemoradiotherapy for stage III non-small cell lung cancer: Does the type of chemotherapy regimen matter?",

abstract = "Objectives:Symptomatic brain metastases (BM) occur frequently after chemoradiotherapy (CRT) for stage III NSCLC. Aim of the current study was to determine whether the specific chemotherapy used in a CRT regimen influences BM development. Materials and methods:Retrospective multicenter study including all consecutive stage III NSCLC who completed CRT. Primary endpoints: symptomatic BM development, whether this was the only site of first relapse. Differences between regimens were assessed with a logistic regression model including known BM risk factors and the specific chemotherapy: concurrent versus sequential (cCRT/sCRT), within cCRT: daily low dose cisplatin (LDC)-cyclic dose polychemotherapy; LDC-(non-)taxane cyclic dose; LDC{\textendash}polychemotherapy subgroups of ≥50 patients. Results:Between January 2006 and June 2014, 838 patients were eligible (737 cCRT, 101 sCRT). 18.2\% developed symptomatic BM, 8.0\% had BM as only site of first relapse. BM patients were significantly younger, female, had more advanced N-stage and had adenocarcinoma histology. In both cCRT and sCRT BM were found in 18\% (p = 0.904). In cyclic dose cCRT (N = 346) and LDC (N = 391) BM were found in 18.8\% and 17.9\%, respectively (p = 0.757). In 7.2\% and 8.7\%, respectively, BM were the only site of first relapse (p = 0.463). The chemotherapy used (cCRT versus sCRT) had no influence on BM development, not for all brain relapses nor as only site of first relapse (OR 0.88 (p = 0.669), OR 0.93 (p = 0.855), respectively). LDC versus cyclic dose cCRT was not significantly different: neither for all brain relapses nor as only site of first relapse (OR 0.96 (p = 0.819), OR 1.21 (p = 0.498), respectively). Comparable results were found for LDC versus cyclic dose non-taxane (N = 277) and cyclic dose taxane regimens (N = 69) and for cCRT regimens with ≥50 patients (LDC versus cisplatin/etoposide (N = 188), cisplatin/vinorelbin (N = 65), weekly cisplatin/docetaxel (N = 60)). Conclusion:approximately 18\% developed symptomatic BM after stage III diagnosis, not dependent on type of chemotherapy regimen used within a CRT treatment.",

author = "Hendriks, \{Lizza E.L.\} and Brouns, \{Anita J.W.M.\} and Mohammad Amini and Wilma Uyterlinde and Robin Wijsman and Jan Bussink and Bonne Biesma and Oei, \{S. Bing\} and Stigt, \{Jos A.\} and Bootsma, \{Gerben P.\} and Belderbos, \{Jos{\'e} S.A.\} and \{De Ruysscher\}, \{Dirk K.M.\} and \{Van den Heuvel\}, \{Michel M.\} and Dingemans, \{Anne Marie C.\}",

note = "Publisher Copyright: {\textcopyright} 2016 Elsevier Ireland Ltd",

year = "2016",

month = nov,

doi = "10.1016/j.lungcan.2016.09.008",

language = "English",

volume = "101",

pages = "68--75",

journal = "Lung Cancer",

issn = "0169-5002",

publisher = "Elsevier Ireland Ltd",

}

Hendriks, LEL, Brouns, AJWM, Amini, M, Uyterlinde, W, Wijsman, R, Bussink, J, Biesma, B, Oei, SB, Stigt, JA, Bootsma, GP, Belderbos, JSA, De Ruysscher, DKM, Van den Heuvel, MM & Dingemans, AMC 2016, 'Development of symptomatic brain metastases after chemoradiotherapy for stage III non-small cell lung cancer: Does the type of chemotherapy regimen matter?', Lung Cancer, vol. 101, pp. 68-75. https://doi.org/10.1016/j.lungcan.2016.09.008

TY - JOUR

T1 - Development of symptomatic brain metastases after chemoradiotherapy for stage III non-small cell lung cancer

T2 - Does the type of chemotherapy regimen matter?

AU - Hendriks, Lizza E.L.

AU - Brouns, Anita J.W.M.

AU - Amini, Mohammad

AU - Uyterlinde, Wilma

AU - Wijsman, Robin

AU - Bussink, Jan

AU - Biesma, Bonne

AU - Oei, S. Bing

AU - Stigt, Jos A.

AU - Bootsma, Gerben P.

AU - Belderbos, José S.A.

AU - De Ruysscher, Dirk K.M.

AU - Van den Heuvel, Michel M.

AU - Dingemans, Anne Marie C.

PY - 2016/11

Y1 - 2016/11

N2 - Objectives:Symptomatic brain metastases (BM) occur frequently after chemoradiotherapy (CRT) for stage III NSCLC. Aim of the current study was to determine whether the specific chemotherapy used in a CRT regimen influences BM development. Materials and methods:Retrospective multicenter study including all consecutive stage III NSCLC who completed CRT. Primary endpoints: symptomatic BM development, whether this was the only site of first relapse. Differences between regimens were assessed with a logistic regression model including known BM risk factors and the specific chemotherapy: concurrent versus sequential (cCRT/sCRT), within cCRT: daily low dose cisplatin (LDC)-cyclic dose polychemotherapy; LDC-(non-)taxane cyclic dose; LDC–polychemotherapy subgroups of ≥50 patients. Results:Between January 2006 and June 2014, 838 patients were eligible (737 cCRT, 101 sCRT). 18.2% developed symptomatic BM, 8.0% had BM as only site of first relapse. BM patients were significantly younger, female, had more advanced N-stage and had adenocarcinoma histology. In both cCRT and sCRT BM were found in 18% (p = 0.904). In cyclic dose cCRT (N = 346) and LDC (N = 391) BM were found in 18.8% and 17.9%, respectively (p = 0.757). In 7.2% and 8.7%, respectively, BM were the only site of first relapse (p = 0.463). The chemotherapy used (cCRT versus sCRT) had no influence on BM development, not for all brain relapses nor as only site of first relapse (OR 0.88 (p = 0.669), OR 0.93 (p = 0.855), respectively). LDC versus cyclic dose cCRT was not significantly different: neither for all brain relapses nor as only site of first relapse (OR 0.96 (p = 0.819), OR 1.21 (p = 0.498), respectively). Comparable results were found for LDC versus cyclic dose non-taxane (N = 277) and cyclic dose taxane regimens (N = 69) and for cCRT regimens with ≥50 patients (LDC versus cisplatin/etoposide (N = 188), cisplatin/vinorelbin (N = 65), weekly cisplatin/docetaxel (N = 60)). Conclusion:approximately 18% developed symptomatic BM after stage III diagnosis, not dependent on type of chemotherapy regimen used within a CRT treatment.

AB - Objectives:Symptomatic brain metastases (BM) occur frequently after chemoradiotherapy (CRT) for stage III NSCLC. Aim of the current study was to determine whether the specific chemotherapy used in a CRT regimen influences BM development. Materials and methods:Retrospective multicenter study including all consecutive stage III NSCLC who completed CRT. Primary endpoints: symptomatic BM development, whether this was the only site of first relapse. Differences between regimens were assessed with a logistic regression model including known BM risk factors and the specific chemotherapy: concurrent versus sequential (cCRT/sCRT), within cCRT: daily low dose cisplatin (LDC)-cyclic dose polychemotherapy; LDC-(non-)taxane cyclic dose; LDC–polychemotherapy subgroups of ≥50 patients. Results:Between January 2006 and June 2014, 838 patients were eligible (737 cCRT, 101 sCRT). 18.2% developed symptomatic BM, 8.0% had BM as only site of first relapse. BM patients were significantly younger, female, had more advanced N-stage and had adenocarcinoma histology. In both cCRT and sCRT BM were found in 18% (p = 0.904). In cyclic dose cCRT (N = 346) and LDC (N = 391) BM were found in 18.8% and 17.9%, respectively (p = 0.757). In 7.2% and 8.7%, respectively, BM were the only site of first relapse (p = 0.463). The chemotherapy used (cCRT versus sCRT) had no influence on BM development, not for all brain relapses nor as only site of first relapse (OR 0.88 (p = 0.669), OR 0.93 (p = 0.855), respectively). LDC versus cyclic dose cCRT was not significantly different: neither for all brain relapses nor as only site of first relapse (OR 0.96 (p = 0.819), OR 1.21 (p = 0.498), respectively). Comparable results were found for LDC versus cyclic dose non-taxane (N = 277) and cyclic dose taxane regimens (N = 69) and for cCRT regimens with ≥50 patients (LDC versus cisplatin/etoposide (N = 188), cisplatin/vinorelbin (N = 65), weekly cisplatin/docetaxel (N = 60)). Conclusion:approximately 18% developed symptomatic BM after stage III diagnosis, not dependent on type of chemotherapy regimen used within a CRT treatment.

UR - https://www.scopus.com/pages/publications/84987880344

U2 - 10.1016/j.lungcan.2016.09.008

DO - 10.1016/j.lungcan.2016.09.008

M3 - Article

C2 - 27794410

AN - SCOPUS:84987880344

SN - 0169-5002

VL - 101

SP - 68

EP - 75

JO - Lung Cancer

JF - Lung Cancer

ER -

Development of symptomatic brain metastases after chemoradiotherapy for stage III non-small cell lung cancer: Does the type of chemotherapy regimen matter?

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this